Thermo Fisher Scientific Inc. $TMO Stock Position Raised by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.6% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,965 shares of the medical research company’s stock after acquiring an additional 9,100 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Thermo Fisher Scientific were worth $23,502,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rossby Financial LCC lifted its holdings in shares of Thermo Fisher Scientific by 6.1% in the 2nd quarter. Rossby Financial LCC now owns 1,714 shares of the medical research company’s stock worth $695,000 after purchasing an additional 98 shares during the last quarter. Peregrine Capital Management LLC bought a new stake in Thermo Fisher Scientific in the second quarter valued at $734,000. Lipe & Dalton bought a new position in shares of Thermo Fisher Scientific during the second quarter worth about $3,813,000. Y Intercept Hong Kong Ltd increased its holdings in shares of Thermo Fisher Scientific by 297.7% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 31,565 shares of the medical research company’s stock worth $12,798,000 after acquiring an additional 23,628 shares during the period. Finally, CCLA Investment Management boosted its stake in Thermo Fisher Scientific by 19.0% during the 2nd quarter. CCLA Investment Management now owns 317,881 shares of the medical research company’s stock valued at $128,837,000 after purchasing an additional 50,695 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Cowen reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday. Finally, Wells Fargo & Company boosted their price target on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $595.75.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $564.49 on Tuesday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The company’s 50-day moving average price is $505.57 and its two-hundred day moving average price is $454.34. The stock has a market cap of $213.16 billion, a PE ratio of 32.61, a price-to-earnings-growth ratio of 3.35 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the previous year, the company posted $5.28 EPS. The business’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $56,937,881. This trade represents a 0.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,666 shares of company stock valued at $13,990,971 in the last quarter. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.